<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863018</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1019</article-id><article-id pub-id-type="other">EPV0278</article-id><article-id pub-id-type="pii">S0924933824010198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Development and Validation of the Isotretinoin Hesitancy Scale</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Agaoglu</surname><given-names>E.</given-names></name><xref rid="aff2311" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yilmaz-Karaman</surname><given-names>I. G.</given-names></name><xref rid="aff2312" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0875" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yastibas-Kacar</surname><given-names>C.</given-names></name><xref rid="aff2313" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kaya-Erdogan</surname><given-names>H.</given-names></name><xref rid="aff2311" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mutlu</surname><given-names>T.</given-names></name><xref rid="aff2311" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Acer</surname><given-names>E.</given-names></name><xref rid="aff2311" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff2311"><sup>1</sup>Dermatology</aff><aff id="aff2312"><sup>2</sup>Psychiatry, <institution>Eski&#x0015f;ehir Osmangazi University</institution>, <city>Eski&#x0015f;ehir</city></aff><aff id="aff2313"><sup>3</sup>Psychology, <institution>Adana Alparslan T&#x000fc;rke&#x0015f; Science and Technology University</institution>, <city>Adana</city>, <country>T&#x000fc;rkiye</country></aff><author-notes><corresp id="cor0875"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="994">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S490</fpage><lpage>S491</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824010198a.pdf"/><abstract><sec id="sec5262"><title>Introduction</title><p>Isotretinoin is an effective treatment for acne vulgaris; however, many patients experience anxiety while deciding to get it. Isotretinoin, indeed, has significant adverse effects. On the other hand, effective treatment of acne vulgaris may reduce dermatological and psychiatric complications.</p></sec><sec id="sec5263"><title>Objectives</title><p>The present study aims to develop and validate the Isotretionin Hesitancy Scale to measure the patients&#x02019; drawbacks to the treatment.</p></sec><sec id="sec5264"><title>Methods</title><p>The specialists, including dermatologists and mental health professionals, determined an item pool of 30 items. Before the data collection, all items were checked by the researchers in terms of clarity and acceptability. Thus, the eight items were removed from the questionnaire due to having similar meanings, measuring the facts about treatments that are not the study&#x02019;s objective, and containing unclear statements. The final version of the questionnaire, which consists of 22 items, was applied to the participants.</p></sec><sec id="sec5265"><title>Results</title><p>One hundred patients with acne vulgaris were recruited. Among the participants, 72% were women, and the mean age was 22.72. Most patients&#x02019; acne severity was group 2 (40%) and group 3 (36%). Three items were removed because of having low item-total score correlations. Five items were removed in factor analysis because of low factor loading or cross-loading. Exploratory factor analysis results of the scale are presented in Table 1.<table-wrap position="anchor" id="tab18"><label>
Table 1.</label><caption><p>Exploratory Factor Analysis Results of the Scale</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">
Factor 1<break/>(min-max)</th><th align="center" valign="middle" rowspan="1" colspan="1">
Factor 2<break/>(min-max)</th><th align="center" valign="middle" rowspan="1" colspan="1">
Factor 3<break/>(min-max)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Isotretinoin treatment can lead to dryness of lips, nose, and eyes.<break/>Isotretinoin treatment may have many side effects.<break/>Isotretinoin treatment may cause damage to the liver.<break/>Side effects of isotretinoin treatment may affect my daily life.<break/>Isotretinoin treatment may cause depression.<break/>Isotretinoin treatment may cause elevation of cholesterol level.</td><td align="center" valign="middle" rowspan="1" colspan="1">0.516-0.842</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Isotretinoin treatment may cause infertility in men.<break/>Isotretinoin treatment may cause infertility in women.<break/>Isotretinoin treatment may prevent height gain.<break/>In case of pregnancy, isotretinoin treatment may cause congenital defects in the baby.</td><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.425-0.945</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">I&#x02019;m afraid of using isotretinoin for a long period.<break/>I stop the isotretinoin treatment as soon as possible.<break/>I will wait as long as I can before using isotretinoin treatment.<break/>I need more reassurance about isotretinoin treatment.</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">0.569-0.890</td></tr></tbody></table><graphic xlink:href="S0924933824010198-TABU0018" position="anchor"/></alternatives></table-wrap></p><p>The Cronbach alpha score of the final form of the scale was found to be .81, the internal consistency of the first factor (hesitancy related to reversible adverse effects) was calculated as&#x000a0;.79, the second factor (hesitancy related to irreversible adverse effects) was calculated as .78, and the final factor (isotretinoin-related anxiety) was found to be .72.</p></sec><sec id="sec5266"><title>Conclusions</title><p>The Isotretionin Hesitancy Scale is valid and reliable among patients with acne vulgaris.</p></sec><sec id="sec5267"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>